ALK Inhibitor in Metastatic Colorectal Cancer With ALK Mutation.

NIAID Data Ecosystem2026-03-11 收录

靶向治疗

KRAS突变结直肠癌

数据链接：

https://www.omicsdi.org/dataset/ecrin-mdr-crc/2293470 数据链接链接失效反馈

官方服务：

资源简介：

This clinical trial aims to evaluate the efficacy, safety of ALK inhibitor in Metastatic Colorectal Cancer Patients with ALK mutation.

创建时间：

2019-03-15

PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies [ChIP-seq]. Homo sapiens

癌症表观遗传学

靶向治疗

The polycomb repressive complex 2 (PRC2) exerts oncogenic effects in many tumour types1. However, loss-of-function mutations in PRC2 components occur in a subset of haematopoietic malignancies, sugges

NIAID Data Ecosystem60

Inactivation of p21-Activated Kinase 2 (Pak2) Inhibits the Development of Nf2-Deficient Tumors by Restricting Downstream Hedgehog and Wnt Signaling

肿瘤分子机制

靶向治疗

Since loss of the NF2 tumor suppressor gene results in p21-activated kinase (Pak) activation, PAK inhibitors hold promise for the treatment of NF2-deficient tumors. To test this possibility, we asked

NIAID Data Ecosystem50

A targetable pathway in neutrophils mitigates both arterial and venous thrombosis. A targetable pathway in neutrophils mitigates both arterial and venous thrombosis

血栓形成机制

靶向治疗

Arterial and venous (A/V) thrombosis constitutes the greatest source of morbidity and mortality worldwide. Long considered as distinct entities, accumulating evidence indicates that A/V thrombosis can

NIAID Data Ecosystem30

Systemic oxaliplatin or in intra-arterial chemotherapy combined with LV5FU2 +/- Irinotecan and targeted therapy in first-line treatment of metastatic colorectal cancer restricted to the liver

结肠直肠癌

靶向治疗

Primary objectives: Comparison of radiological and/or clinical progression free survival between the arm with intraarterial oxaliplatin administration (Arms A and C) and those with intravenous oxalipl

NIAID Data Ecosystem60

Supplementary Table SI from Targeting Small Cell Lung Cancer Harboring PIK3CA Mutation with a Selective Oral PI3K Inhibitor PF-4989216

靶向治疗

药物筛选

Supplementary Table SI XLS file 19K, Supplementary Table SI: Kinase selectivity of PF-4989216

aacr.figshare.com2023-05-31 更新40